Seer, Inc.

Seer, Inc. announced preliminary data at the 2026 ASMS Annual Conference, demonstrating the potential of its Proteograph Product Suite for AI-driven multi-cancer screening. The findings, from a collaboration with Korea University, involved analyzing over 5,500 plasma samples across ten cancer types. Researchers reported deep and reproducible plasma proteome coverage, averaging over 14,000 protein groups per sample, and are developing an ID-Free AI framework to leverage complex proteomic datasets for improved screening strategies. The collaboration aims to analyze over 20,000 clinical plasma samples.

Seer, Inc. issued a letter to stockholders urging them to vote "FOR" the election of its seven director nominees at the upcoming Annual Meeting on July 28, 2026. The company is actively opposing two activist stockholders, Bradley Radoff and Michael Torok, who have submitted unqualified director nominations and unsolicited acquisition proposals priced below the company's cash value. Seer highlighted its clear strategy, rapid scientific validation, accelerating commercial momentum, disciplined financial management including share buybacks, and robust innovation pipeline to support its current board and strategy.

Seer, Inc. has filed definitive proxy materials for its Annual Meeting on July 28, 2026, urging stockholders to vote "FOR" its seven director nominees. The company is actively defending against a proxy fight initiated by activist stockholders Bradley Radoff and Michael Torok, who are attempting to acquire Seer at a significant discount. Seer highlights its clear strategy, strong governance, and long-term value creation opportunity, while criticizing Radoff and Torok's short-term, self-interested campaign. The company also noted financial discipline, including reduced operating expenses and share repurchases.

Seer, Inc. announced it has filed a complaint with the United States International Trade Commission (ITC) against Nanomics Biotechnology Co., Ltd., with Brigham and Women's Hospital joining the action. The complaint alleges infringement of five U.S. patents related to nanoparticle protein enrichment, building on a prior federal district court suit. Seer seeks an investigation and an exclusion order to prevent Nanomics' Proteonano kits and workstations from entering the U.S., emphasizing its commitment to protecting its pioneering technology and product integrity.

Seer, Inc. announced its participation at the 2026 American Society for Mass Spectrometry (ASMS) Annual Conference, where it will showcase advancements in its Proteograph Product Suite. Key highlights include a preview of AI-driven proteomics for multi-cancer screening in collaboration with Korea University, analyzing over 20,000 clinical plasma samples. Seer will also introduce next-generation data processing tools, Radiant DIA and Fulcrum Pipeline, designed to significantly reduce runtime for large-scale proteomics studies. Additionally, numerous customer-led scientific presentations will demonstrate the growing adoption of Seer's technology across various research applications.

Seer, Inc.'s Board of Directors unanimously rejected a further revised unsolicited non-binding acquisition proposal from the Radoff-JEC Group. The May 14, 2026 proposal offered $2.40 per share in cash plus a contingent value right. The Board determined the offer significantly undervalues Seer and its long-term growth prospects, noting it was materially similar to a previously rejected proposal and below the company's current cash value.

Seer, Inc. announced that its Board of Directors has unanimously rejected the further revised unsolicited non-binding proposal from Bradley L. Radoff and Michael Torok (Radoff-JEC Group). The proposal offered to acquire all outstanding shares of Seer's Class A common stock for $2.40 per share in cash plus a contingent value right. The Board determined the offer significantly undervalues Seer and its long-term growth prospects, noting it implies an equity value below the company's current cash and investments.

Seer, Inc. reported its first quarter 2026 financial results, showing a decrease in total revenue to $2.79 million from $4.21 million in the prior year. Despite the revenue decline, the company's net loss improved to $(16.84) million from $(19.95) million, driven by reduced operating expenses. Additionally, the Board of Directors authorized an extra $25.0 million for share repurchases and adopted a Tax Benefit Preservation Plan to protect its net operating losses.

Seer, Inc. reported first quarter 2026 financial results, with revenue decreasing 34% year-over-year to $2.8 million, primarily due to a depressed academic funding environment and competitive activity. Despite the revenue decline, the company improved its net loss to $16.8 million from $19.9 million in the prior year, driven by a 20% reduction in operating expenses. Seer reaffirmed its full-year 2026 revenue guidance of $16 million to $18 million and highlighted strategic achievements including a collaboration with Precision Health Research, Singapore, and the repurchase of approximately 1.5 million shares.

Seer, Inc. announced the appointment of Anthony Bazarko as its new Chief Commercial Officer, effective May 4, 2026. Mr. Bazarko brings over two decades of extensive commercial leadership experience from various life sciences, diagnostics, and biotechnology companies, including Biologos, Specific Diagnostics, Danaher Corporation, and Roche Diagnostics. In his new role, he will lead Seer's Sales, Marketing, and Customer Experience organizations to accelerate the adoption of the Proteograph® Product Suite and drive the company's next phase of growth.